Key facts
- It has raised $34.0M across 3 recorded rounds; the latest was Later Stage VC (Series A2) ($9.0M) in Jan 2023.
- Mantra Bio has filed 1 Form D with the SEC, most recently Aug 2020 ($30.1M sold to 31 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Mantra Bio
Create free account
No card required
Funding rounds
3 roundsJan 2023Later Stage VC (Series A2)$9.0M▮
Jul 2020Early Stage VC (Series A)$25.0M▮
Jan 2018Accelerator/Incubator—▮
About Mantra Bio
- Industry
- Drug Delivery
PA Mark — not yet priced
Mantra Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Mantra Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Mantra Bio in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.